Welcome to our dedicated page for Arbutus Biopharm news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharm stock.
Arbutus Biopharma Corp (NASDAQ: ABUS) generates news primarily through clinical trial updates, scientific conference presentations, and corporate milestones in its pursuit of hepatitis B virus (HBV) cure therapies. As a clinical-stage biopharmaceutical company, Arbutus regularly reports on the progress of its drug candidates through the development pipeline.
News coverage for Arbutus typically includes clinical trial data readouts for imdusiran and AB-101, the company's lead HBV drug candidates. Investors and researchers monitoring HBV therapeutic development follow these updates closely, as trial results shape understanding of whether combination approaches can achieve functional cure. Conference presentations at major hepatology meetings provide additional scientific detail beyond press releases.
Quarterly financial reports reveal the company's cash position and operating expenses, critical metrics for clinical-stage biotechs that rely on financing rather than product revenue. These reports often coincide with pipeline updates and forward-looking guidance on clinical timelines. Partnership announcements and licensing deals related to Arbutus's lipid nanoparticle (LNP) technology platform also generate coverage.
Regulatory interactions, including FDA communications and clinical trial design decisions, inform expectations about development pathways. Board and leadership changes affect corporate strategy and investor sentiment. For those tracking the competitive HBV cure landscape, Arbutus news provides insight into one focused player's progress toward transforming chronic infection treatment.
Bookmark this page to follow Arbutus Biopharma's clinical development progress and corporate updates as the company advances its hepatitis B cure programs.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in the virtual fireside chat at the Jefferies London Healthcare Conference on November 18, 2021, at 8:00 am GMT / 3:00 am ET. Key executives, including CEO William Collier and Chief Scientific Officer Dr. Michael Sofia, will present during the event. A webcast will be available through Arbutus' website, with a replay accessible after the conference. The company focuses on developing treatments for chronic hepatitis B virus and coronaviruses, leveraging a diverse pipeline aimed at innovative solutions.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported its Q3 2021 financial results, highlighting key developments in its hepatitis B virus (HBV) treatment pipeline. The company has initiated a Phase 2a trial combining AB-729 with standard NA therapy and Peg-IFNα-2a, aiming for multiple data readouts in Q4 2021. Financially, Arbutus reported a net loss of $24.2 million, a slight increase from $21.8 million year-over-year. The company also extended its cash runway into Q2 2023, with $151.9 million in cash on hand as of September 30, 2021, amidst rising R&D expenses.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the presentation of data on its GalNAc-siRNA, AB-729, at The Liver Meeting® 2021, occurring from November 12-15, 2021. The poster, titled "Low HBsAg levels maintained following cessation of the GalNAc-siRNA, AB-729," indicates that AB-729 is generally safe and demonstrates sustained HBsAg decline in chronic hepatitis B patients. Key findings show maintained HBsAg suppression in some patients for up to 20 weeks post-treatment.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its schedule for the Q3 2021 financial results and corporate update on November 4, 2021. The press release will be available at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. Investors can access the live webcast via the company's website. Arbutus is focused on developing treatments for chronic hepatitis B and coronaviruses, leveraging a diverse portfolio of assets.
Arbutus Biopharma Corporation (Nasdaq: ABUS) focuses on innovative therapies to combat chronic hepatitis B virus (HBV) infections and coronaviruses, including COVID-19. On September 28, 2021, the company announced participation in two key virtual investor conferences in October. The first is Chardan's 5th Annual Genetic Medicines Conference on October 4-5, featuring a fireside chat on October 5 at 4:30 PM ET. The second is the H.C. Wainwright HBV Virtual Conference on October 13, with a fireside chat at 1:00 PM ET. Webcast links are available on Arbutus' website, along with archived replays.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the appointment of Lisa M. Caperelli as Vice President of Investor Relations, a newly created role. Caperelli, with 20 years of experience in investor relations within the biotech sector, will head strategy and communications reporting to CFO David Hastings. This change aims to enhance engagement with the investment community regarding Arbutus’ efforts in providing a functional cure for chronic hepatitis B and ongoing coronavirus therapies. Caperelli previously held roles at various biotech companies, including Harmony Biosciences.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its participation in two upcoming virtual investor conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021, featuring a fireside chat on September 13 at 7:00 am ET. The second is the Cantor Global Healthcare Conference from September 27-30, 2021, with a formal presentation on September 30 at 8:40 am ET. Presenters include the company's CEO and scientific leaders. Webcast links for both events are available via Arbutus' website.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced significant advancements in its hepatitis B virus (HBV) pipeline, particularly AB-729, showcased in four abstracts at the EASL International Liver Congress™. The drug received FDA authorization for a Phase 2a trial, focusing on safety and antiviral activity when combined with nucleos(t)ide analog therapy. The press release highlighted two new collaborations to evaluate AB-729’s combination potential. Financially, Arbutus reported a net loss of $22.7 million for Q2 2021, with cash reserves of $121.3 million, sufficient for operations into Q3 2022.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021, at 4:05 PM ET. The fireside chat will feature key executives, including President and CEO William Collier and Chief Scientific Officer Dr. Michael Sofia. A live webcast will be accessible via the Investors section of Arbutus' website, with an archive available post-conference. The company focuses on developing a cure for chronic hepatitis B virus (HBV) and therapies for coronaviruses, including COVID-19.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its plans to release its second quarter 2021 financial results on August 5, 2021, at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. The company focuses on developing a cure for chronic hepatitis B and therapies for coronaviruses, including COVID-19. A live webcast will be accessible on their website, and an archived version will be available post-event. Investors can dial in using designated numbers for domestic and international participants.
FAQ
What is the current stock price of Arbutus Biopharm (ABUS)?
What is the market cap of Arbutus Biopharm (ABUS)?
